Why This Crypto Skeptic Had a Change of Heart

He used to make fun of crypto. Now... he says one $3 crypto could rise to $92 by next year.

Ondas Holdings Stock Is Hitting New 52-Week Highs Today: Here's Why

Alex Perry
October 02, 2025

Shares of Ondas Holdings Inc. (NASDAQ:ONDS) are soaring Thursday after the autonomous drone infrastructure company said it placed a significant purchase order.

What To Know: Ondas announced that it placed its initial order of 500 WÃ¥sp drones from Rift Dynamics, a Norwegian drone company, to launch U.S. defense market distribution through its American Robotics subsidiary.

The WÃ¥sp is combat-ready drone designed to meet growing demand from the U.S.’s recently renamed Department of War (DOW), previously called the Department of Defense, for “mass affordable” strike and perimeter defense platforms.

“Demand from the U.S. Department of War and allied defense forces for mass-affordable attritable platforms is accelerating, and the WÃ¥sp is engineered to meet that requirement,” Ondas CEO Eric Brock said.

“Leveraging Rift’s NDAA-compliant design and Kitron proven global manufacturing expertise, Ondas is able [to] rapidly scale production and deliver thousands of units per month.”

Kitron, a defense manufacturer based in the U.S., will be in charge of producing the initial 500 drones. The total will eventually scale to more than 20,000 units per month within six months. Ondas is actively pursuing contracts with the DOW and said it expects to receive its initial deliveries of WÃ¥sp systems in the fourth quarter of 2025.

“We are thrilled Rift Dynamics has chosen Kitron as a manufacturing partner to support its growth and we are well positioned to meet that demand,” said Gary Tarallo, Kitron’s managing director of US Operations.

ONDS Price Action: Ondas shares were up 25.65% at $9.18 at the time of publication on Thursday, according to Benzinga Pro. Ondas stock is making new 52-week highs on Thursday.

Read More:

  • From AI To Delivery Drones: Defiance’s JEDI ETF Targets Next-Gen Autonomy

Image: Drone-Photo/Shutterstock.com

Continue Reading...

Popular

Donald Trump's Approval Rating Crashes to Record Low — Here's What's Driving the Decline

According to the recent YouGov/Economist poll, President Trump's approval rating has taken a nosedive, reaching its lowest point in his second term.

Bitcoin Struggles Around $112,000, But Here's Why The Bull Run Is Not Over Yet

Bitcoin's (CRYPTO: BTC) is languishing around $112,000, but a prominent trader remains adamant about a strong end to the year.

Want To Know the No.1 Crypto and the No.1 Stock? - Ad

The #1 crypto is just $3. Crypto analysts say a cash injection could drive it as high as $100 in the next year. The #1 stock is equally exciting. It's less than $10 but made a HUGE deal recently to work with Nvidia.

Consumer Tech News (Sep. 15 – Sep. 19): Fed Rate Cut Lifts Wall Street To Records As Meta Unveils Smart Glasses, Nvidia-Intel Forge Chip Pact

Wall Street rallied to record highs after the Fed's rate cut, while Meta launched new smart glasses, Nvidia teamed with Intel on chips, and big names like General Mills, FedEx, and Darden reported earnings.

New Biotech Offering Targets $426B Rare Disease Market - Ad

The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.

Harvard Business School graduate arrested on charges he cheated fellow alums out of over $4 million

NEW YORK (AP) — A Harvard Business School graduate was arrested Thursday on fraud charges alleging he swindled fellow alumni of the prestigious school out of over $4 million in a Ponzi scheme, even assuring one investor they would soon “brag” about their “crazy gains” at the school's reunion.

BlackRock Turns Popular Mutual Funds Into Global Equity ETFs

BlackRock turns two top mutual funds into active ETFs, giving investors global equity exposure and strategies to manage volatility.

Rare Disease Biotech Offers Access Ahead of Key Milestone - Ad

This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.

Block CEO Jack Dorsey Invites Businesses Using Square PoS System To Test Bitcoin Payments Feature

Jack Dorsey, co-founder and CEO of Block Inc. (NYSE:XYZ), on Monday encouraged merchants using the company's Square platform to test Bitcoin (CRYPTO: BTC) payments.

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.

US jobless aid applications retreat to 231,000 after surging to nearly 4-year high a week earlier

The number of Americans applying for jobless aid last week retreated significantly after surging to a nearly four-year high a week earlier.

Amazon spends $1 billion to increase pay and lower health care costs for US workers

NEW YORK (AP) — Amazon says it's making a $1 billion investment to raise wages and lower the cost of health care plans for its U.S. fulfillment and transportation workers.

Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad

A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.

Spain sweltered under hottest summer on record

MADRID (AP) — Spain said Tuesday that this summer was the hottest on record for the southern European nation, which like the entire Mediterranean region is being hard hit by climate change.

Opendoor Is A 'Stock That Could Be The Amazon Of Housing': Eric Jackson

Eric Jackson sees Opendoor as able to simplify the experience of buying and selling a home in the same way that Amazon revolutionized retail.

Elon's $25 Trillion Confession - Ad

Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.

Scam centers are spreading in East Timor, UN report says

BANGKOK (AP) — A suspected scam call operation and a suspicious network of companies was discovered with links to a new free trade zone in East Timor, the U.N. Office of Drugs and Crime said Thursday.

How the Multiplier Effect is Working on This $3 Crypto - Ad

It's called the multiplier effect in crypto. In short, because of a lack of supply, small inflows of cash can create major moves in the overall value of the crypto. And it's particularly strong in one $3 crypto. Crypto analysts are suggesting it could rise to as high as $100 by next year.

Bitcoin Gets The Jitters Around $115,000: Up Or Down Ahead Of FOMC Day?

Bitcoin's (CRYPTO: BTC) tapped $116,000 before retracing below $115,000 on Monday, signaling that fresh catalysts may be needed to lift sentiment as weakening metrics signal a potential pullback.

Time to Say Goodbye to "Old" Dollar? Say Hello to "Trump's New Dollar" - Ad

If you have any money in U.S. dollars... learn how to prepare for "Trump's new dollar"... Because this could be the biggest change to our financial system in 54 years. President Trump even called it: "The greatest revolution in financial technology since the birth of the internet itself."

Australia warns social media platforms against age verification for all ahead of a ban on children

MELBOURNE, Australia (AP) — Australian authorities said Tuesday that should not demand age verification for all account holders starting from December, when a having accounts goes into effect in the country.

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

The "Mar-A-Lago Accord" Is Now Underway - Ad

The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)

Lam Research And JSR Resolve Legal Disputes As They Team Up On AI Era Chips

Lam Research and JSR Corp agreed to collaborate and cross-license, combining their expertise to accelerate semiconductor manufacturing and reduce costs.

Crypto Is The Money For AI, Says Economist As Coinbase CEO Teases Stablecoin-Powered Transactions Between Agents

Renowned economist Alex Tabbarok described cryptocurrencies as the “money” for artificial intelligence on Tuesday after Coinbase Global Inc. (NASDAQ:COIN) CEO teased a new feature that enables AI agents to transact using stablecoins.

Why This Crypto Skeptic Had a Change of Heart - Ad

He used to make fun of crypto. Now... he says one $3 crypto could rise to $92 by next year.

Why Redwire Stock Is Gaining Today

Redwire climbs about 4% after subsidiary Edge Autonomy wins a European NATO ally contract to supply Stalker Group 2 reconnaissance drone.

Want To Know the No.1 Crypto and the No.1 Stock? - Ad

The #1 crypto is just $3. Crypto analysts say a cash injection could drive it as high as $100 in the next year. The #1 stock is equally exciting. It's less than $10 but made a HUGE deal recently to work with Nvidia.

Tesla Model Y Fails Teen's Road Test — Marked 'Out of Order' Mid-Exam

Using a Tesla Model Y for a driver's training test may be a bad idea, with another example of a failure due to advanced vehicle features.

New Biotech Offering Targets $426B Rare Disease Market - Ad

The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.

SciSparc Stock Shoots Up Over 89% After Hours: What's Going On?

SciSparc's stock surged 89.13% to $3.48 after-hours on news of a court-granted stay in its merger with AutoMax, though the stock remains down 71.87% over the past year.

Lyft Finds Its Robotaxi Mojo—But Uber's Still In The Fast Lane

Lyft scores a 10% stock pop on its first robotaxi deal with Alphabet's Waymo. But can it compete with Uber's global reach and dominance?

Rare Disease Biotech Offers Access Ahead of Key Milestone - Ad

This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.

UREVO Pushes Into US Wellness Market With New Ecosystem, Expects 50% Sales Surge in 2025

UREVO, the home fitness and wellness company, is making a strong bet on the U.S. market with its new wellness ecosystem, forecasting about 50% sales growth in 2025.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright priceactionea.net
Privacy Policy | Terms of Service